Properties
What is it?
International Nonproprietary Name - fluticasone propionate, salmeterol Clinical-pharmacological group: Glucocorticoids → Inhaled glucocorticoid preparations Qualitative and quantitative composition Plastic molded device containing foil strips with 28 or 60 blisters. Each blister contains 50 micrograms of salmeterol in the form of salmeterol xinafoate and 100 micrograms of fluticasone propionate. Plastic molded device containing foil strips with 28 or 60 blisters. Each blister contains 50 micrograms of salmeterol in the form of salmeterol xinafoate and 250 micrograms of fluticasone propionate. Plastic molded device containing foil strips with 28 or 60 blisters. Each blister contains 50 micrograms of salmeterol in the form of salmeterol xinafoate and 500 micrograms of fluticasone propionate. Pharmaceutical form Inhalation powder Indications Asthma (reversible obstructive airway disease) Seretide is indicated for the regular treatment of asthma (reversible obstructive airway disease). This may include: Patients who are on an effective long-term maintenance dose of long-acting beta-agonists and are using inhaled corticosteroids. Patients who experience symptoms despite ongoing inhaled corticosteroid therapy. Patients who are receiving regular bronchodilator therapy and require inhaled corticosteroids. Chronic Obstructive Pulmonary Disease (COPD) Seretide is indicated for the regular treatment of chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. It has been shown to reduce mortality. Dosage and administration Seretide Accuhaler/Diskus is for inhalation use only. Patients should be advised to use Seretide regularly to achieve optimal effect, even when asymptomatic. Regular review by a doctor is necessary to ensure that the strength of Seretide remains optimal and is only changed on medical advice. Asthma (reversible obstructive airway disease) Dose titration is required down to the lowest dose that is effective for symptom control. When symptom control is maintained with twice-daily Seretide, titration may proceed to the lowest effective dose once daily. Patients should receive an adequate amount of Seretide containing an appropriate dose of fluticasone propionate for the severity of their disease. If a patient is inadequately controlled on inhaled corticosteroid therapy alone, substitution with Seretide at therapeutically effective doses of corticosteroids may lead to improvement in asthma control. For patients whose asthma is controlled on inhaled corticosteroid therapy alone, substitution with Seretide may allow a reduction in corticosteroid dose for asthma control. For further information. Recommended doses: Adults and adolescents aged 12 years and older One inhalation (50 mcg salmeterol or 100 mcg fluticasone propionate) twice daily or One inhalation (50 mcg salmeterol or 250 mcg fluticasone propionate) twice daily or One inhalation (50 mcg salmeterol or 500 mcg fluticasone propionate) twice daily. Children aged 4 years and older One inhalation (50 mcg salmeterol or 100 mcg fluticasone propionate) twice daily There is no data on the use of Seretide in children under 4 years of age. Chronic Obstructive Pulmonary Disease (COPD) The recommended dose for adult patients is one inhalation of 50/250 micrograms - 50/500 micrograms salmeterol/fluticasone propionate twice daily. At a dose of 50/500 micrograms twice daily, Seretide reduces mortality. Special patient populations No dose adjustment is necessary in patients with renal or hepatic impairment.